IXHL · Company research
Incannex Healthcare Limited (IXHL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| IXHL261016C00004000 Interactive Stock Chart | IXHL Oct 2026 4.000 call Stock - Yahoo Finance | IXHL261016C00004000 Interactive Stock Chart | IXHL Oct 2026 4.000 call Stock Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight | Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bullish | 1 | 1 |
| Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight | Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bullish | 1 | 1 |
| IXHL Oct 2026 3.000 call (IXHL261016C00003000) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore | IXHL Oct 2026 3.000 call (IXHL261016C00003000) interactive stock chart – Yahoo Finance Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 9, 2026 | neutral | 0 | 0.6 |
| A company with about $70 million in cash and no debt is testing a sleep-apnea treatment. - Stock Titan | A company with about $70 million in cash and no debt is testing a sleep-apnea treatment. Stock Titan | View source ↗ | Stock Titan | Sep 9, 2026 | neutral | 0 | 0.6 |
| Sleep-apnea candidate showed up to 83% fewer breathing interruptions; Incannex doses first patient - Stock Titan | Sleep-apnea candidate showed up to 83% fewer breathing interruptions; Incannex doses first patient Stock Titan | View source ↗ | Stock Titan | Aug 25, 2026 | neutral | 0 | 0.6 |
| Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X - Yahoo Finance | Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X Yahoo Finance | View source ↗ | Yahoo Finance | Jul 15, 2026 | neutral | 0 | 0.6 |
| IXHL Forecast — Price Target — Prediction for 2027 - TradingView | IXHL Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| Biopharmaceutical company Incannex Healthcare Ltd (IXHL) receives inaugural coverage report from Alliance Global Partners. - Bitget | Biopharmaceutical company Incannex Healthcare Ltd (IXHL) receives inaugural coverage report from Alliance Global Partners. Bitget | View source ↗ | Bitget | Jun 8, 2026 | neutral | 0 | 0.6 |
| IXHL Should I Buy - Intellectia AI | IXHL Should I Buy Intellectia AI | View source ↗ | Intellectia AI | Mar 31, 2026 | neutral | 0 | 0.6 |
| IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits | IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms Stocktwits | View source ↗ | Stocktwits | Mar 12, 2026 | neutral | 0 | 0.6 |
| Sleep apnea pill from Incannex cut apnea events by up to 83% in trial - Stock Titan | Sleep apnea pill from Incannex cut apnea events by up to 83% in trial Stock Titan | View source ↗ | Stock Titan | Mar 12, 2026 | neutral | 0 | 0.6 |
| Market Movers | Winners: IXHL, ALBT, RXT | Losers: THRY, EOSE, ERII - Trefis | Market Movers | Winners: IXHL, ALBT, RXT | Losers: THRY, EOSE, ERII Trefis | View source ↗ | Trefis | Feb 26, 2026 | neutral | 0 | 0.6 |
| Why Did IXHL Stock Tank Over 32% Today? - Stocktwits | Why Did IXHL Stock Tank Over 32% Today? Stocktwits | View source ↗ | Stocktwits | Feb 25, 2026 | neutral | 0 | 0.6 |
| Incannex Healthcare Inc. Announces 1-for-30 Reverse Stock Split to Regain Nasdaq Compliance | IXHL Stock News - Quiver Quantitative | Incannex Healthcare Inc. Announces 1-for-30 Reverse Stock Split to Regain Nasdaq Compliance | IXHL Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Feb 25, 2026 | neutral | 0 | 0.6 |
| Incannex Healthcare (IXHL) Institutional Ownership 2026 - MarketBeat | Incannex Healthcare (IXHL) Institutional Ownership 2026 MarketBeat | View source ↗ | MarketBeat | Feb 23, 2026 | neutral | 0 | 0.6 |
| Should I buy Incannex Healthcare Inc. (IXHL) - Zacks Investment Research | Should I buy Incannex Healthcare Inc. (IXHL) Zacks Investment Research | View source ↗ | Zacks Investment Research | Dec 1, 2025 | neutral | 0 | 0.6 |
| What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock - Yahoo Finance | What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock Yahoo Finance | View source ↗ | Yahoo Finance | Dec 1, 2025 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.